Immune Checkpoint Inhibition in Early-Stage TNBC

Downloadable slideset describing neoadjuvant and adjuvant immunotherapy in high-risk, early-stage triple-negative breast cancer.
Denise A. Yardley, MD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 548 KB
Released: September 15, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Related Content

Enter details about your patient with HER2+ MBC into this online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Aditya Bardia, MD, MPH Sara Hurvitz, MD, FACP Komal Jhaveri, MD Heather McArthur, MD, MPH Sara Tolaney, MD, MPH Released: November 23, 2022

Expert slides on nursing care for patients receiving CAR T-cells, including managing acute and long-term toxicities, from Clinical Care Options (CCO)

person default Kathryn Ciccolini, DNP, AGACNP-BC, OCN Linda Ramsdell, MSN, FNP-BC, OCN Released: November 17, 2022

Expert commentary with Dr Charles Geyer on the essential need for BRCA testing in early breast cancer to guide adjuvant olaparib decisions, from Clinical Care Options (CCO) and ProCE

Charles E. Geyer, Jr., MD Released: November 17, 2022

A patient describes her journey with early breast cancer and the critical role of good communication between patients and their healthcare providers in this short video by Clinical Care Options (CCO)

person default Zoe Lanham Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings